Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5491826 | 0.82 | APLNR (0.35) | KMT2A | |
| SCHEMBL9278174 | 0.81 | KMT2A (0.31) | KMT2A | |
| SCHEMBL9754770 | 0.81 | GAA (0.31) | GAAL3MBTL1 | |
| SCHEMBL475361 | 0.81 | APLNR (0.38) | KMT2AGAAL3MBTL1 | |
| SCHEMBL8599635 | 0.79 | CHRNB2 (0.32) | GAAL3MBTL1 | |
| SCHEMBL1933219 | 0.79 | GAA (0.48) | KMT2AGAAL3MBTL1 | |
| SCHEMBL13225973 | 0.79 | GAA (0.48) | KMT2AGAAL3MBTL1 | |
| SCHEMBL12539711 | 0.79 | KMT2A (0.31) | KMT2AGAAL3MBTL1 | |
| SCHEMBL13225974 | 0.79 | GAA (0.48) | KMT2AGAAL3MBTL1 | |
| SCHEMBL1433982 | 0.76 | ATM (0.33) | KMT2AGAAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 724 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4100010-B1 | NITROXIDE COMPOUNDS FOR USE IN THE TREATMENT OF OPIOID-INDUCED RESPIRATORY DEPRESSION (OIRD) | UNIV CASE WESTERN RESERVE (US) | 2026-01-07 | — | — | EP | claimed |
| EP-4648746-A1 | TOPICAL COMPOSITIONS AND METHODS FOR TREATING ALOPECIA | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2025-11-19 | — | — | EP | claimed |
| WO-2025085492-A1 | BORANE REDUCING REAGENTS | EXACT SCIENCES CORPORATION (US) | 2025-04-24 | — | — | WO | claimed |
| US-20250041285-A1 | MODIFYING THE EXPRESSION LEVEL OF A GENE ENCODING AN CYCLOOXYGENASE ENZYME BY TREATING A HUMAN SUBJECT WITH A NITROXIDE | HABASH LOUIS (US) | 2025-02-06 | — | — | US | claimed |
| US-12208089-B2 | Adjusting expression level of a gene encoding a Sirtuin protein by treating a human subject with a nitroxide | HABASH LOUIS (US) | 2025-01-28 | — | — | US | claimed |
| US-20250011861-A1 | BISULFITE-FREE, BASE-RESOLUTION IDENTIFICATION OF CYTOSINE MODIFICATIONS | LUDWIG INSTITUTE FOR CANCER RESEARCH LTD. (CH) | 2025-01-09 | — | — | US | claimed |
| US-20240415826-A1 | MODULATING EXPRESSION LEVEL OF A GENE ENCODING AN UNCOUPLING PROTEIN BY TREATING A HUMAN SUBJECT WITH A NITROXIDE | HABASH LOUIS (US) | 2024-12-19 | — | — | US | claimed |
| WO-2024150216-A1 | TOPICAL COMPOSITIONS AND METHODS FOR TREATING ALOPECIA | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2024-07-18 | — | — | WO | claimed |
| US-11998536-B2 | Decreasing expression level of proteasome subunit genes by treating a human subject with a nitroxide | HABASH LOUIS (US) | 2024-06-04 | — | — | US | claimed |
| US-11987843-B2 | Bisulfite-free, base-resolution identification of cytosine modifications | LUDWIG INSTITUTE FOR CANCER RESEARCH, LTD (CH) | 2024-05-21 | — | — | US | claimed |
| WO-1998055684-A1 | MULTI-COMPONENT SYSTEM FOR MODIFYING, DECOMPOSING OR BLEACHING LIGNIN, MATERIALS CONTAINING LIGNIN OR SIMILAR SUBSTANCES AND METHODS FOR PRODUCING THE SAME | Consortium für elektrochemische Industrie GmbH (DE) | 1998-12-10 | — | — | WO | claimed |
| US-5773635-A | ALDOL CONDENSATION; IN PRESENCE OF OXYGEN OR NITRIC OXIDE | BASF AKTIENGESELLSCHAFT (DE) | 1998-06-30 | — | — | US | claimed |
| US-5714510-A | Topical proxyl composition and method | PROCTOR PETER H (US) | 1998-02-03 | — | — | US | claimed |
| EP-0691329-B1 | Process for the preparation of polyencarbonyl compounds with high content of the all E-isomer and their acetals or ketales | BASF AG (DE) | 1997-10-29 | — | — | EP | claimed |
| US-5610249-A | FREE RADICAL CATALYST, ORGANIC PHOSPHORUS COMPOUND | KANSAI PAINT CO., LTD. (JP) | 1997-03-11 | — | — | US | claimed |
| EP-0691329-A1 | Process for the preparation of polyencarbonyl compounds with high content of the all E-isomer and their acetals or ketales | BASF AKTIENGESELLSCHAFT (DE) | 1996-01-10 | — | — | EP | claimed |
| US-5401874-A | Nitroxide free radical catalysts for oxidation of alkoxy alkanols | SHELL OIL COMPANY (US) | 1995-03-28 | — | — | US | claimed |
| EP-0327263-B1 | Hair growth stimulation with nitroxide and other radicals | PROCTOR PETER H (US) | 1994-09-07 | — | — | EP | claimed |
| WO-1988005653-A1 | TOPICAL COMPOSITION FOR STIMULATING HAIR GROWTH WITH STABLE FREE RADICALS | PROCTOR PETER H (US) | 1988-08-11 | — | — | WO | claimed |
| US-3993131-A | Tracing flow of petroleum in underground reservoirs | CITIES SERVICE COMPANY (US) | 1976-11-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11998536-B2 | Decreasing expression level of proteasome subunit genes by treating a human subject with a nitroxide | PSMD4, PSMD2, PSMD1 | KMT2A 1566/4885GAA 760/4885L3MBTL1 713/4885 |
| US-20250041285-A1 | MODIFYING THE EXPRESSION LEVEL OF A GENE ENCODING AN CYCLOOXYGENASE ENZYME BY TREATING A HUMAN SUBJECT WITH A NITROXIDE | HMOX2, QSOX1, GPX1 | KMT2A 1174/4885GAA 2682/4885L3MBTL1 814/4885 |
| US-12208089-B2 | Adjusting expression level of a gene encoding a Sirtuin protein by treating a human subject with a nitroxide | SIRT2, SIRT6, TXNRD2 | KMT2A 341/4885GAA 3501/4885L3MBTL1 928/4885 |
| US-20240415826-A1 | MODULATING EXPRESSION LEVEL OF A GENE ENCODING AN UNCOUPLING PROTEIN BY TREATING A HUMAN SUBJECT WITH A NITROXIDE | TXNRD2, TXN2, TXNRD1 | KMT2A 2072/4885GAA 3880/4885L3MBTL1 1401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.